Catalent launched a delayed-release technology called OptiGel DR, which allows softgel capsules to be formed by combining pectin with gelatin to eliminate the need for a separate capsule-coating step.
Photo © iStockphoto.com/MarsBars
Catalent (Somerset, NJ) launched a delayed-release technology called OptiGel DR, which allows softgel capsules to be formed by combining pectin with gelatin to eliminate the need for a separate capsule-coating step. This technology can be used in pharmaceutical and nutraceutical applications. Delayed release technology protects active ingredients from stomach acid, so they are released in directly in the intestines, potentially enhancing bioavailability.
“Catalent has a long history in softgel innovation, stretching back more than 85 years, and this latest evolution of the technology allows innovators to design the most efficient products, and bring superior pharmaceutical and nutraceutical products to the marketplace,” said Aris Gennadios, PhD, Catalent’s president for softgel and oral technologies, in a press release. “The technology we have developed allows the delayed release profile to be incorporated into the softgel capsule shell, broadening the applications, and making a separate capsule coating step unnecessary. This reduces time and yield loss and eliminates potential quality issues associated with coated softgels.”
OptiGel DR capsules can also help reduce gastric reflux effects, and they eliminate the processing and performance challenges associated with conventionally coated delayed release softgels.
Kratom sees impressive sales growth despite its regulatory status and stigma
March 12th 2025Despite its controversy, kratom is a top-selling ingredient that consumers see value in. That said, brands need to work hard to demonstrate safety and quality of kratom products in the absence of legal regulatory status. Will kratom be able to overcome its stigma for even more growth and consumer acceptance?
DOJ asks Utah court to dismiss FTC lawsuit against Xlear Inc.
March 11th 2025On March 10, the DOJ and the defendant filed a stipulation to dismiss with prejudice the lawsuit in which each party agrees “to be responsible for its own costs and fees and agrees that no party shall be responsible to any other party for any fines, costs, fees, or penalties arising from this case.”
HHS announces efforts to eliminate independent conclusion of GRAS
Published: March 11th 2025 | Updated: March 11th 2025U.S. Department of Health and Human Services (HHS) Secretary, Robert F. Kennedy Jr., is directing the acting U.S. Food and Drug Administration’s (FDA) acting commissioner to explore rulemaking that would eliminate the independent conclusion of GRAS provision.